2008- review: Inhaled anticholinergics increase risk for major cardiovascular events in chronic obstructive pulmonary disease

Stanbrook, Matthew B.
January 2009
ACP Journal Club;1/1/2009, Vol. 150 Issue 1, p4
Academic Journal
The article presents author's comments on a study titled "Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis," by researcher S. Singh and colleagues. It states that Singh and colleagues' decision to pool placebo-controlled trials with trials using active comparators is questionable. It informs that contradictory findings may reflect differences in individual trial characteristics.


Related Articles

  • Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Barr, R. G.; Bourbeau, J.; Camargo, C. A.; Ram, F. S. F. // Thorax;Oct2006, Vol. 61 Issue 10, p854 

    Background: A systematic review was undertaken to evaluate the efficacy of tiotropium, a long acting anticholinergic drug, on clinical events, symptom scales, pulmonary function, and adverse events in stable chronic obstructive pulmonary disease (COPD). Methods: A systematic search was made of...

  • Inhaled anticholinergics: increased risk of major adverse CV events?  // Reactions Weekly;10/4/2008, Issue 1222, p3 

    The article reports on the study of the association of inhaled anticholinergics and the risk of cardiovascular events in patients with chronic obstructive pulmonary disease (COPD). Results showed that use of the anticholinergics ipratropium bromide and tiotropium bromide appears to increase the...


    The article discusses research being done on the impact of anticholinergic agents on patients diagnosed with chronic obstructive pulmonary disease (COPD). It references a study by Sonal Singh and colleagues, published in the September 24, 2008 issue of the "Journal of the American Medical...

  • Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications. Singh, Sonal; Loke, Yoon K.; Enright, Paul; Furberg, Curt D. // Postgraduate Medical Journal;Apr2014, Vol. 89 Issue 1062, p205 

    The majority of deaths in COPD are from cardiovascular causes. Several large randomized controlled trials demonstrate that inhaled anticholinergic agents ipratropium and tiotropium increase the risk of serious cardiovascular events, including cardiovascular mortality. Tiotropium Respimat is...

  • Tiotropium beats LABA in COPD. Swan, David // Pulse;9/26/2012, Vol. 72 Issue 31, p14 

    The article presents a study according to which Tiotropium, an anticholinergic bronchodilator is more effective than a long-acting beta- agonist in preventing chronic obstructive pulmonary disease (COPD).

  • Meta-analysis: Anticholinergics reduce COPD exacerbations more effectively than beta-2 agonists.  // Formulary;Sep2006, Vol. 41 Issue 9, p430 

    The article reports on the results of the meta-analysis published online by the "Journal of General Internal Medicine." Researchers extracted randomized trials of the two medication classes in chronic obstructive pulmonary disease (COPD) patients. The researchers found that patients who received...

  • Meta-analysis: Anticholinergics, but notβ-agonists, Reduce Severe Exacerbations and Respiratory Mortality in COPD. Salpeter, Shelley R.; Buckley, Nicholas S.; Salpeter, Edwin E. // JGIM: Journal of General Internal Medicine;Oct2006, Vol. 21 Issue 10, p1011 

    BACKGROUND: Anticholinergics and β2-agonists have generally been considered equivalent choices for bronchodilation in chronic obstructive pulmonary disease (COPD). OBJECTIVE: To assess the safety and efficacy of anticholinergics and β2-agonists in COPD. DESIGN: We comprehensively searched...

  • Beta-Blockers Reduced the Risk of Mortality and Exacerbation in Patients with COPD: A Meta-Analysis of Observational Studies. Du, Qingxia; Sun, Yongchang; Ding, Ning; Lu, Lijin; Chen, Ying // PLoS ONE;Nov2014, Vol. 9 Issue 11, p1 

    Background: Cardiovascular disease is a primary cause of death in patients with chronic obstructive pulmonary disease (COPD). Beta-blockers have been proved to reduce morbidity and improve survival in patients with cardiac diseases. But the effects of beta-blockers on outcomes in patients with...

  • Inhaled Long-Acting β-Agonists Versus Anticholinergics in Older Patients With Chronic Obstructive Pulmonary Disease. Fabbri, Leonardo M.; Vogelmeier, Claus; Rabe, Klaus F.; Stanbrook, Matthew B.; Gershon, Andrea // Annals of Internal Medicine;10/18/2011, Vol. 155 Issue 8, p561 

    A letter to the editor is presented in response to the article "Comparison of inhaled long-acting β–agonist and anticholinergic effectiveness in older patients with chronic obstructive pulmonary disease: a cohort study," by A. Gershon and colleagues in an issue of 2011 and a response...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics